IgM nephropathy
A kidney disorder characterized by the presence of IgM antibodies in the glomeruli
IgM nephropathy is a kidney disorder characterized by the presence of immunoglobulin M (IgM) antibodies in the glomeruli, which are the filtering units of the kidney. This condition is considered a form of glomerulonephritis, a group of diseases that cause inflammation of the glomeruli.
Pathophysiology
IgM nephropathy is marked by the deposition of IgM antibodies in the mesangial areas of the glomeruli. The exact mechanism by which IgM contributes to kidney damage is not fully understood. However, it is believed that the presence of IgM may activate the complement system, leading to inflammation and damage to the glomerular structure. This can result in impaired kidney function and proteinuria, where excess protein is found in the urine.
Clinical Presentation
Patients with IgM nephropathy may present with a variety of symptoms, including:
- Proteinuria
- Hematuria
- Hypertension
- Edema
The severity of symptoms can vary widely among individuals. Some patients may have mild symptoms, while others may progress to more severe kidney damage.
Diagnosis
The diagnosis of IgM nephropathy is typically made through a kidney biopsy. Under a microscope, the biopsy will show mesangial deposits of IgM antibodies. Immunofluorescence microscopy is often used to confirm the presence of IgM in the glomeruli.
Treatment
Treatment for IgM nephropathy is not standardized and can vary depending on the severity of the disease. Common approaches include:
- Corticosteroids to reduce inflammation
- Immunosuppressive drugs
- Angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs) to control blood pressure and reduce proteinuria
Prognosis
The prognosis for patients with IgM nephropathy varies. Some individuals may experience a benign course with minimal kidney damage, while others may progress to chronic kidney disease or even end-stage renal disease. Regular monitoring and management of symptoms are crucial to improving outcomes.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
